Evaluation of 99mTc-HYNIC-MPG as a novel SPECT radiotracer to detect EGFR-activating mutations in NSCLC
Metrics: PDF 1313 views | HTML 1730 views | ?
Zunyu Xiao1,2, Yan Song1,2, Wang Kai1,2, Xilin Sun1,2 and Baozhong Shen1,2
1TOF-PET/CT/MR Center, The Fourth Hospital of Harbin Medical University, Harbin, China
2Molecular Imaging Research Center, Harbin Medical University, Harbin, China
Xilin Sun, email: [email protected]
Baozhong Shen, email: [email protected]
Keywords: 99mTc, HYNIC-MPG, SPECT imaging, mutant EGFR, non small cell lung cancer (NSCLC)
Received: September 28, 2016 Accepted: April 06, 2017 Published: April 19, 2017
Tyrosine kinase inhibitors (EGFR-TKIs) targeting the epidermal growth factor receptor (EGFR) have been used in non-small cell lung carcinoma (NSCLC) for years with promising results, in particular in patients with activating mutations in the EGFR kinase domain (exon 19 E746-A750 deletion or exon 21 L858R point mutation). However, despite their great success in the clinic, a significant number of patients do not respond to EGFR-TKIs, such as those carrying the L858R/T790M mutation or EGFR wild type. Thus, detecting the EGFR mutation status before EGFR-TKIs therapy is essential to ensure its efficacy. In this study, we report a novel SPECT tracer 99mTc-HYNIC-MPG that binds specifically to activating mutant EGFR and which could therefore be used to noninvasively select patients sensitive to EGFR-TKIs. We evaluated the capacity of 99mTc-HYNIC-MPG in detecting EGFR-activating mutations both in vitro and in vivo using four human NSCLC cell lines (PC9, H1975, H358 and H520). 99mTc-HYNIC-MPG had significantly higher accumulation in PC9 tumor cells when compared to H1975, H358 and H520 tumors cells, which may be due to the activating mutations (exon 19 deletion) in EGFR tyrosine kinase domain in PC9 cells. Thus, 99mTc-HYNIC-MPG SPECT imaging may be used to identify NSCLC tumors with a potential high response rate to EGFR-TKIs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.